Dexclamol
Antipsychotic compound
From Wikipedia, the free encyclopedia
Dexclamol (AY 24169) was an investigational new drug developed by McKenna and Harrison, Ltd. that was evaluated as a antipsychotic.[1][2][3][4] It acts as a dopamine receptor antagonist.[1]
| Clinical data | |
|---|---|
| Other names | AY 24169 |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H29NO |
| Molar mass | 347.502 g·mol−1 |
| 3D model (JSmol) | |
| |
| |